* participation in any other clinical trial of an experimental treatment for covid-19 * concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited \< 24 hours prior to study drug dosing * evidence of multiorgan failure * mechanically ventilated \[including veno-venous (v-v) extracorporeal membrane oxygenation (ecmo)\] ≥ 5 days, or any duration of veno-arterial (v-a) ecmo. * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 x upper limit of normal (uln) * creatinine clearance \< 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants \< 18 years of age note: other protocol defined inclusion/exclusion criteria may apply.

* participation in any other clinical trial of an experimental treatment for covid-19 * concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited \< 24 hours prior to study drug dosing * evidence of multiorgan failure * mechanically ventilated \[including veno-venous (v-v) extracorporeal membrane oxygenation (ecmo)\] ≥ 5 days, or any duration of veno-arterial (v-a) ecmo. * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5 x upper limit of normal (uln) * creatinine clearance \< 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants \< 18 years of age note: other protocol defined inclusion/exclusion criteria may apply.

- participation in any other clinical trial of an experimental treatment for covid-19 - concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study drug dosing - evidence of multiorgan failure - mechanically ventilated [including veno-venous (v-v) extracorporeal membrane oxygenation (ecmo)] ≥ 5 days, or any duration of veno-arterial (v-a) ecmo. - alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln) - creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of age note: other protocol defined inclusion/exclusion criteria may apply.

- participation in any other clinical trial of an experimental treatment for covid-19 - concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study drug dosing - evidence of multiorgan failure - mechanically ventilated [including veno-venous (v-v) extracorporeal membrane oxygenation (ecmo)] ≥ 5 days, or any duration of veno-arterial (v-a) ecmo. - alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln) - creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of age note: other protocol defined inclusion/exclusion criteria may apply.

- participation in any other clinical trial of an experimental treatment for covid-19 - concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study drug dosing - evidence of multiorgan failure - mechanically ventilated (including v-v ecmo) ≥ 5 days, or any duration of v-a ecmo. - alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln) - creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of age note: other protocol defined inclusion/exclusion criteria may apply.

- participation in any other clinical trial of an experimental treatment for covid-19 - concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to study drug dosing - evidence of multiorgan failure - mechanically ventilated (including v-v ecmo) ≥ 5 days, or any duration of v-a ecmo. - alanine aminotransferase (alt) or aspartate aminotransferase (ast) > 5 x upper limit of normal (uln) - creatinine clearance < 50 ml/min using the cockcroft-gault formula for participants ≥ 18 years of age {cockcroft 1976} and schwartz formula for participants < 18 years of age note: other protocol defined inclusion/exclusion criteria may apply.